Clinical Trial Update: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluated the combination of liposomal doxorubicin (Doxil) and bortezomib in patients with refractory hematologic cancers or mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm
• Ovarian Cancer
• Unspecified Adult Solid Tumor

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Breast Cancer, Leukemia | Phase 1, Phase 2 | Status: COMPLETED